HK1198121A1 - Therapeutic combinations of netupitant and palonosetron - Google Patents
Therapeutic combinations of netupitant and palonosetron Download PDFInfo
- Publication number
- HK1198121A1 HK1198121A1 HK14110976.1A HK14110976A HK1198121A1 HK 1198121 A1 HK1198121 A1 HK 1198121A1 HK 14110976 A HK14110976 A HK 14110976A HK 1198121 A1 HK1198121 A1 HK 1198121A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ibs
- combination
- amount
- use according
- netupitant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548514P | 2011-10-18 | 2011-10-18 | |
| US201161548514P | 2011-10-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14108329.9A Addition HK1194977B (en) | 2011-10-18 | 2012-10-10 | Therapeutic combinations of netupitant and palonosetron |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14108329.9A Division HK1194977B (en) | 2011-10-18 | 2012-10-10 | Therapeutic combinations of netupitant and palonosetron |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1198121A1 true HK1198121A1 (en) | 2015-03-13 |
Family
ID=47178220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK14110976.1A HK1198121A1 (en) | 2011-10-18 | 2014-08-14 | Therapeutic combinations of netupitant and palonosetron |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9358228B2 (enExample) |
| EP (2) | EP2744497B1 (enExample) |
| JP (1) | JP2014530249A (enExample) |
| CN (3) | CN106974912A (enExample) |
| DK (1) | DK2744497T3 (enExample) |
| ES (1) | ES2579616T3 (enExample) |
| HK (1) | HK1198121A1 (enExample) |
| HU (1) | HUE030811T2 (enExample) |
| PL (1) | PL2744497T3 (enExample) |
| PT (1) | PT2744497T (enExample) |
| WO (1) | WO2013057554A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20200196T1 (hr) * | 2016-06-06 | 2020-05-01 | Helsinn Healthcare Sa | Fiziološki balansirane injektabilne formulacije fosnetupitanta |
| CN108721214B (zh) * | 2017-04-14 | 2020-06-16 | 和龙 | 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途 |
| TW202428273A (zh) | 2023-01-03 | 2024-07-16 | 瑞士商赫爾辛保健公司 | 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU642178B2 (en) | 1989-11-28 | 1993-10-14 | Roche Palo Alto Llc | New tricyclic compounds |
| US5510486A (en) | 1994-07-26 | 1996-04-23 | Syntex (U.S.A.) Inc. | Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
| WO2000048581A2 (en) * | 1999-02-18 | 2000-08-24 | Novartis Ag | Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| EP1035115B1 (en) | 1999-02-24 | 2004-09-29 | F. Hoffmann-La Roche Ag | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists |
| PT1303490E (pt) | 2000-07-14 | 2008-09-04 | Hoffmann La Roche | Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina |
| DK1349541T3 (da) | 2000-12-14 | 2007-01-08 | Hoffmann La Roche | Selvemulgerende lipidmatrix (SELM) |
| KR20050111318A (ko) * | 2003-01-13 | 2005-11-24 | 다이노젠 파마세우티컬스, 인코포레이티드 | 기능성 장 질환을 치료하는 방법 |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| JO2676B1 (en) * | 2004-04-06 | 2012-06-17 | جانسين فارماسوتيكا ان. في | Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines |
| CN101006074B (zh) | 2004-07-01 | 2012-02-15 | 欧科生医股份有限公司 | 作为nk1拮抗剂的哌啶衍生物 |
| WO2007128056A1 (en) * | 2006-05-03 | 2007-11-15 | Cnsbio Pty Ltd | Methods and composition for treatment of inflammatory pain |
| EA016455B1 (ru) | 2006-10-24 | 2012-05-30 | Хелсинн Хелткэр С.А. | Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность |
| WO2009000038A1 (en) | 2007-06-28 | 2008-12-31 | Cnsbio Pty Ltd | Combination methods and compositions for treatment of neuropathic pain |
| PE20121483A1 (es) * | 2009-11-18 | 2012-12-02 | Helsinn Healthcare Sa | Composiciones para tratar nausea y vomito centralmente mediados |
-
2012
- 2012-10-10 WO PCT/IB2012/002013 patent/WO2013057554A2/en not_active Ceased
- 2012-10-10 PL PL12784677.2T patent/PL2744497T3/pl unknown
- 2012-10-10 PT PT127846772T patent/PT2744497T/pt unknown
- 2012-10-10 DK DK12784677.2T patent/DK2744497T3/en active
- 2012-10-10 HU HUE12784677A patent/HUE030811T2/hu unknown
- 2012-10-10 EP EP12784677.2A patent/EP2744497B1/en active Active
- 2012-10-10 JP JP2014536344A patent/JP2014530249A/ja active Pending
- 2012-10-10 ES ES12784677.2T patent/ES2579616T3/es active Active
- 2012-10-10 CN CN201610834008.7A patent/CN106974912A/zh active Pending
- 2012-10-10 CN CN201510670710.XA patent/CN105412110B/zh active Active
- 2012-10-10 EP EP14165604.1A patent/EP2759298B1/en active Active
- 2012-10-10 CN CN201280051509.8A patent/CN103889423B/zh active Active
- 2012-10-10 US US14/351,113 patent/US9358228B2/en active Active
-
2014
- 2014-08-14 HK HK14110976.1A patent/HK1198121A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103889423A (zh) | 2014-06-25 |
| CN105412110A (zh) | 2016-03-23 |
| CN105412110B (zh) | 2018-05-25 |
| US9358228B2 (en) | 2016-06-07 |
| JP2014530249A (ja) | 2014-11-17 |
| EP2759298A1 (en) | 2014-07-30 |
| DK2744497T3 (en) | 2016-08-01 |
| HK1194977A1 (zh) | 2014-10-31 |
| PT2744497T (pt) | 2016-07-18 |
| US20140256737A1 (en) | 2014-09-11 |
| ES2579616T3 (es) | 2016-08-12 |
| CN106974912A (zh) | 2017-07-25 |
| HUE030811T2 (hu) | 2017-05-29 |
| EP2744497A2 (en) | 2014-06-25 |
| WO2013057554A3 (en) | 2013-07-11 |
| PL2744497T3 (pl) | 2016-10-31 |
| CN103889423B (zh) | 2016-10-19 |
| EP2759298B1 (en) | 2018-01-17 |
| WO2013057554A2 (en) | 2013-04-25 |
| EP2744497B1 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sang et al. | AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans | |
| HUP0303983A2 (hu) | Peptidvegyületek új alkalmazása az allodynia vagy más krónikus vagy fantom típusú fájdalom kezelésére | |
| Mickle et al. | Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process | |
| EP2759298B1 (en) | Therapeutic combinations of netupitant and palonosetron | |
| JP4746714B2 (ja) | 線維筋痛症治療用医薬組成物 | |
| Durrani et al. | Comparative efficacy (sedative and anaesthetic) of detomidine, ketamine and detomidine-ketamine cocktail in pigeons (columba livia). | |
| Moyao-García et al. | A pilot study of nalbuphine versus tramadol administered through continuous intravenous infusion for postoperative pain control in children | |
| KR20120103557A (ko) | 파킨슨씨병 치료용 조성물 및 치료방법 | |
| Simon et al. | The antinociceptive effects of intravenous administration of three doses of butorphanol tartrate or naloxone hydrochloride following hydromorphone hydrochloride to healthy conscious cats | |
| KR102374820B1 (ko) | 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물 | |
| HK1194977B (en) | Therapeutic combinations of netupitant and palonosetron | |
| KR102927058B1 (ko) | 진통 가려움 완화 약학 조성물 및 그 응용 방법 | |
| MXPA06006685A (es) | Uso de gaboxadol para tratar el insomnio. | |
| JP2014530249A5 (enExample) | ||
| Kulkarni et al. | The role of intrathecal midazolam as an adjunct to bupivacaine in providing post-operative pain relief | |
| Forney et al. | Potentiation of ethanol-induced depression in dogs by representative ataractic and analgesic drugs | |
| MM | Clinical evaluation of epidural bupivacaine, butorphanol, and butorphanol-bupivacaine combination in goat | |
| Yu et al. | Transdermal fentanyl for management of cancer pain in elderly patients in China | |
| US12539323B2 (en) | Anti-psychotic composition and treatment methods | |
| JPH0232020A (ja) | モルフィン鎮痛治療における耐性発現の抑制方法および薬剤 | |
| Tammisto et al. | Restlessness and Shivering after Naloxone Reversal of Fentanyl‐supplemented Anaesthesia | |
| Azcona et al. | Effects of the muscarinic agonist RS 86 in healthy volunteers | |
| US20250134903A1 (en) | Compositions and methods for treating pain | |
| Oppel-Sutter | Research Reviews. Pelargonium Root Extract Tablet Tested for Safe and Effective Treatment of Acute Bronchitis. | |
| KR20180037408A (ko) | 락티톨을 포함하는 과민성 대장 증후군 예방 및 치료용 약학적 조성물 |